Phase IV EORTC Quality of Life Module for Patients With Chronic Myeloid Leukemia

An International Field Study for the Reliability and Validity of the Phase IV EORTC Quality of Life Module for Patients With Chronic Myeloid Leukemia (EORTC QLQ-CML24)

The objective of this study is to test the scale structure, reliability, validity and responsiveness to change of the QLQ-CML24 in conjuction with the QLQ-C30 for patients diagnosed with CML, and to investigate longitudinal relationship between satisfaction with information provision and QoL outcomes.

Inclusion Criteria:

• Above 18 years of age.
• Patient with confirmed diagnosis of Philadelphia chromosome positive and/or BCR-ABL positive chronic myeloid leukemia (CML).
• Written informed consent.
• Patients enrolled in investigational drug-trials or other type of clinical trials are also eligible.

Exclusion Criteria:

• Patients with a psychiatric condition or major cognitive impairment (as evaluated by their treating physician) that would hinder completion of self-reported health-related QoL questionnaires.
• Patients who are unable to speak and read the language of the questionnaire.